Search Bar & Filters
Found 9 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the SensMode System, a set of wearable devices designed to analyze upper and lower limb movements. This study involves healthy adults, subjects with idiopathic hyposmia, patients with Parkinsons disease, and individuals with newly diagnosed drug-nafve extrapyramidal syndrome. The goal is to establish normal ranges for objective motor measurements and explore how this technology might aid in early diagnosis and management of Parkinsons disease. Participants will use the SensMode System, which includes SensHand and SensFoot devices. SensHand consists of sensorized rings and a wristband that measure movement and orientation of the hand and forearm, while SensFoot is a device placed over the shoe to assess lower limb motion. All subjects undergo motor analysis using these sensors at enrollment. During the study, researchers will monitor various motor outcome measures such as the number of repetitions of specific movements, time to stand up, gait time, rotation time, fundamental frequencies from accelerometer signals, and stride count at enrollment. This data will help characterize motor function and support further research into Parkinsons disease diagnosis and care. The study runs from May 2024 to January 2026 and includes adults aged 50 to 80 years.
Actively Recruiting
Researchers are conducting a large prospective, observational cohort study to evaluate the clinical impact of new Monoclonal Antibodies MAB in patients with B-cell Non-Hodgkin Lymphoma NHL treated in Italian clinical practice. The study focuses on collecting information about the use, feasibility, effectiveness, and both short- and long-term side effects of novel MABs that have been approved by the European Medicines Agency since 2020 and prescribed according to authorized indications in Italy. Participants will be divided into groups based on treatment indication, antibody type, and lymphoma subtype to allow detailed analysis. The study observes patients with B-cell NHL who have received at least one dose of a novel MAB either alone or in combination, as authorized for use in Italy. Both patients receiving first-line treatment and those with relapsed or refractory disease are included. Various cohorts and sub-cohorts will be analyzed to understand outcomes by indication, antibody type, and histological subtype, providing a comprehensive overview of these treatments in real-life settings. Participants will be followed for at least five years to assess outcomes such as overall response rate, complete response rate, progression-free survival, overall survival, event-free survival, time to next treatment, non-relapse mortality, duration of response, and the incidence of early and late adverse events. Clinical data collection will include treatment details, safety monitoring, and long-term follow-up to evaluate both effectiveness and toxicity. The study spans several years, allowing researchers to capture extensive real-world evidence on novel MAB use in B-cell NHL.
Actively Recruiting
Researchers are evaluating the effects of ninerafaxstat in patients with symptomatic non-obstructive hypertrophic cardiomyopathy nHCM. This global, multicenter, double-blind, placebo-controlled Phase 2b study aims to assess the efficacy and safety of ninerafaxstat compared to placebo when added to standard care for this condition. Participants will receive either ninerafaxstat 200mg modified release tablets or matching placebo tablets, both administered twice daily. The study uses a randomized parallel-group design to compare these treatments over a 12-week period, focusing on changes in patient symptoms and functional status. Throughout the study, participants will undergo cardiopulmonary exercise testing and complete the Kansas City Cardiomyopathy Questionnaire to measure changes in clinical symptoms and physical limitations. The primary outcome is the change in the questionnaires Clinical Summary Score from baseline to week 12. Safety and secondary outcomes related to exercise efficiency and symptom scores will also be monitored. The study is expected to conclude in December 2026.
Actively Recruiting
Researchers are evaluating the safety, tolerability, and effectiveness of ALXN2350 gene therapy in adults with BAG3 mutation associated dilated cardiomyopathy DCM. This Phase 12 open-label study focuses on finding the appropriate dose and expanding the dose range in this population with a specific heart condition linked to a genetic mutation. Participants will receive a single intravenous infusion of ALXN2350, a gene therapy product containing an AAV9 capsid with the BAG3 transgene. The dose varies depending on the cohort, with three different dose levels under study to determine safety and appropriate dosing. During the study, participants will be monitored for adverse events and cardiac health outcomes over time, with assessments up to 78 weeks. These include evaluations of serious side effects, heart function, cardiac events, and biomarkers related to heart failure. The study spans from initial treatment through long-term follow-up to assess the therapys impact and safety.
Actively Recruiting
Researchers are evaluating the clinical characteristics and procedural outcomes of patients receiving permanent cardiac pacing to treat various heart rhythm disorders. This observational study compares the effectiveness and safety of different device implantation methods used in routine clinical practice, including the contribution of advanced non-fluoroscopic anatomical and electrophysiological mapping systems. The study focuses on patients over 18 years old who require a pacemaker or intracardiac defibrillator implant following European Society of Cardiology guidelines. The study includes several types of cardiac pacing approaches conventional right ventricular pacing, conduction system pacing such as His bundle or left bundle branch area pacing, cardiac resynchronization therapy CRT with biventricular or left ventricular pacing, epicardial pacing often done during cardiac surgery, and leadless pacing via a percutaneous femoral vein approach. Each method involves implantation of a device connected to cardiac leads positioned in specific heart locations, with vascular access through veins like the cephalic, axillary, or subclavian. Electrical parameters such as pacing threshold and sensing are measured to ensure device stability before final placement. Participants will be followed for up to 120 months with clinical and procedural data collected, including assessments of device efficacy and safety at 30 days, 6 months, and 12 months. Outcome measures include stable electrical device performance, absence of cardiovascular hospitalizations or death, and monitoring for heart failure or arrhythmia events. The study also tracks procedural times, radiation exposure, and complications such as infections or lead dislocations. This long-term observation aims to understand the benefits and risks of various pacing strategies in real-world settings.
Actively Recruiting
Researchers are conducting a global, prospective, multi-center post-market clinical follow-up study called MANTRA to monitor the safety and performance of CORCYM devices and accessories used for aortic, mitral, and tricuspid valve diseases in real-world settings. This umbrella protocol allows multiple sub-studies to be added, covering the sponsors entire cardiac surgery heart valve portfolio and including core lab assessments for some products. The study plans to enroll about 2150 subjects across up to 130 sites worldwide. The study includes three sub-studies the Aortic Sub-Study, the MitralTricuspid Sub-Study excluding Memo 4D, and the Memo 4D Sub-Study. Subjects diagnosed with valve diseases and considered suitable for treatment with specific CORCYM devices can participate in the corresponding sub-study. Follow-up visits are planned at discharge, 30 days post-implantation, and annually for up to 10 years. The Memo 4D sub-study involves additional echocardiogram imaging assessed by a core lab. Participants will provide informed consent and share baseline, procedural, hospitalization, discharge, and follow-up data during standard medical care. They will complete quality of life questionnaires at baseline, 30 days, and one year. Researchers will monitor device success at 30 days as the primary outcome and track mortality, adverse cardiovascular events, rehospitalizations, valve function, and patient outcomes up to 10 years. Safety and performance data will be collected continuously throughout the study.
Actively Recruiting
Researchers are studying recurrent bacterial vaginosis, a common condition in women of reproductive age caused by an imbalance in vaginal bacteria. This trial evaluates whether a probiotic supplement containing Lactobacillus crispatus CRP21 can reduce the recurrence of bacterial vaginosis compared to a placebo. The study is randomized, double-blind, and placebo-controlled, focusing on women diagnosed with recurrent bacterial vaginosis who have recently completed antibiotic treatment. Participants will be randomly assigned to receive either the probiotic supplement or a placebo capsule daily for 12 weeks following standard antibiotic treatment. The probiotic aims to restore healthy vaginal bacteria, particularly Lactobacillus crispatus, which helps maintain vaginal balance. After the treatment period, participants will be followed for another 12 weeks to monitor for any recurrence of bacterial vaginosis. During the 24-week study, participants will undergo evaluations including vaginal pH measurement, symptom assessments for burning and itching, and monitoring for other genitourinary infections. Researchers will track treatment adherence, safety, and adverse events. The main goal is to see if the probiotic reduces episodes of recurrent bacterial vaginosis compared to placebo over the entire study period.
Actively Recruiting
This registry is designed to support ongoing post-market surveillance for surgical heart valve repair and replacement products used in patients with heart valve disease. It aims to monitor long-term device performance and safety in a real-world setting over an extended period. Participants include patients who have received or are intended to receive surgical heart valve repair or replacement devices. The registry collects information on these devices without assigning treatments, focusing on observing their effects and any adverse outcomes over time. During the study, participants health and device status will be monitored through follow-up assessments. Researchers will track unique device failure modes and trends in adverse effects related to the devices for up to 10 years. Participation duration may vary, with continued data collection to inform device safety and performance.
Actively Recruiting
Researchers are assessing the safety and performance of the SPIKE FLOW endocardial lead, a temporary cardiac pacing device intended for use up to 7 days. This study focuses on patients needing temporary intravenous cardiac pacing due to conditions like acute myocardial infarction, bradycardia, atrioventricular block, and ventricular tachyarrhythmias. The trial aims to measure freedom from serious adverse events and evaluate pacing capture thresholds, impedance, and sensed R-wave amplitude. Participants will receive the SPIKE FLOW lead inserted and removed by trained medical staff according to manufacturers instructions. The lead is single-use and used for temporary pacing during surgical or interventional procedures or when bradycardia is under investigation. The study involves visits at baseline, lead insertion, lead removal, discharge, and 30 days after lead removal, with monitoring of safety and device performance throughout. During the study, participants undergo physical exams, vital sign checks, laboratory tests, electrocardiograms, and echocardiograms at key timepoints. Researchers will track adverse events and device issues from insertion until 30 days after lead removal. The primary outcomes include safety regarding serious adverse events and pacing capture threshold, while secondary measures assess adverse events, pacing impedance, and sensed R-wave amplitude. The total enrollment period is about one year with follow-up extending 30 days post device removal.